益气温阳通脉方对化疗致周围神经病变患者的临床疗效

史海霞; 饶志璟; 祝利民; 鲁叶云; 杨晓露; 盖云; 邓海滨; 徐振晔

doi:10.16306/j.1008-861x.2022.02.003

您当前的位置：

首页 >

文章列表页 >

益气温阳通脉方对化疗致周围神经病变患者的临床疗效

临床研究 | 更新时间：2022-08-29

- 益气温阳通脉方对化疗致周围神经病变患者的临床疗效
- Clinical effect of Yiqi Wenyang Tongmai Formula on patients with chemotherapy induced peripheral neuropathy
- 上海中医药大学学报 2022年36卷第2期页码：13-19
- 作者机构：
  
  1.上海交通大学医学院附属第九人民医院中医科（上海　200011）
  2.上海中医药大学附属龙华医院肿瘤二科（上海　200032）
  3.上海市第十人民医院崇明分院中医肿瘤科（上海　202157）
  4.上海市宝山区中西医结合医院药剂科（上海　201999）
  5.上海中医药大学附属第七人民医院肿瘤科（上海　200137）
- 作者简介：
  
  史海霞，女，博士，主治医师，主要从事中西医结合肿瘤及老年病的临床与基础研究
  徐振晔，主任医师、教授，博士生导师；E-mail： xuzhenye1947@126.com
- 基金信息：
  
  国家中医药管理局全国老中医药专家学术经验继承工作人才培养项目(国中医药人教发〔2017〕29号);上海市教委科研创新计划重大项目(2017-01-07-00-10E0004)
- DOI：10.16306/j.1008-861x.2022.02.003
  中图分类号：
扫描看全文
史海霞,饶志璟,祝利民等.益气温阳通脉方对化疗致周围神经病变患者的临床疗效[J].上海中医药大学学报,2022,36(02):13-19.

SHI Haixia,RAO Zhijing,ZHU Limin,et al.Clinical effect of Yiqi Wenyang Tongmai Formula on patients with chemotherapy induced peripheral neuropathy[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(02):13-19.
史海霞,饶志璟,祝利民等.益气温阳通脉方对化疗致周围神经病变患者的临床疗效[J].上海中医药大学学报,2022,36(02):13-19. DOI： 10.16306/j.1008-861x.2022.02.003.

SHI Haixia,RAO Zhijing,ZHU Limin,et al.Clinical effect of Yiqi Wenyang Tongmai Formula on patients with chemotherapy induced peripheral neuropathy[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(02):13-19. DOI： 10.16306/j.1008-861x.2022.02.003.

摘要

目的,2,观察益气温阳通脉方对化疗致周围神经病变（CIPN）患者的临床疗效。,方法,2,采用随机对照研究方法，纳入135例CIPN患者，随机分为观察组69例、对照组66例。观察组患者给予益气温阳通脉方口服，对照组患者给予甲钴胺片口服，疗程均为2个月。治疗前后，比较两组患者的中医症状积分；评价两组患者的中医证候疗效和周围神经病变分级改善疗效；治疗前后，测定并比较两组患者的正中神经和腓肠神经的感觉神经传导速度（SNCV）、运动神经传导速度（MNCV）；采用总神经病变评分（TNS）量表评价患者的周围神经损伤情况；采用FACT/GOG-Ntx量表评估患者的生活质量。,结果,2,研究中，观察组和对照组分别剔除2例、5例患者，最终纳入统计分析者观察组67例、对照组61例。①治疗后，观察组患者的手足麻木、疼痛、怕冷、乏力神疲症状积分较治疗前均明显降低（,P,<,0.05），对照组患者的手足麻木、疼痛症状积分较治疗前亦降低（,P,<,0.05），且观察组患者的手足麻木、疼痛、怕冷、乏力神疲症状积分均低于对照组（,P,<,0.05）。②治疗后，观察组患者的中医证候疗效总有效率为46.27%，对照组为19.67%，观察组的疗效优于对照组（,P,<,0.05）。③治疗后，观察组患者的周围神经病变分级改善疗效总有效率为85.07%，对照组为80.33%，观察组的疗效优于对照组（,P,<,0.05）。④治疗后，两组患者的正中神经、腓肠神经的SNCV、MNCV较治疗前均明显增快（,P,<,0.05），且观察组患者的正中神经、腓肠神经的SNCV、MNCV较对照组亦明显增快（,P,<,0.05）。⑤治疗后，两组患者的TNS量表评分较治疗前均降低（,P,<,0.05），且观察组患者的评分低于对照组（,P,<,0.05）。⑥治疗后，两组患者的FACT/GOG-Ntx量表评分较治疗前均降低（,P,<,0.05），且观察组患者的评分低于对照组（,P,<,0.05）。,结论,2,与甲钴胺相比，益气温阳通脉方能更好地改善CIPN患者的临床症状及周围神经病变严重程度，提高患者的周围神经传导速度，从而改善患者的生活质量，增加患者抗癌治疗的信心和依从性。

Abstract

Objective： To observe the clinical effect of Yiqi Wenyang Tongmai Formula on the patients with chemotherapy induced peripheral neuropathy （CIPN）.,Methods,2,The randomized controlled trial was carried out. A total of 135 patients with CIPN were selected and randomly divided into the observation group （69 cases） and the control group （66 cases）. The patients in the observation group were orally reated with Yiqi Wenyang Tongmai Formula and the patients in the control group were orally treated with mecobalamin tablets， with a course of 2 months. Before and after treatment， the Chinese medical symptom scores of the two groups were compared. The curative effects on Chinese medical syndrome and the improvement of peripheral neuropathy classification in the two groups were evaluated. Before and after treatment， the sensory nerve conduction velocity （SNCV） and motor nerve conduction velocity （MNCV） of median nerve and sural nerve of patients in the two groups were measured and compared. The total neuropathy score （TNS） scale was used to evaluate the peripheral nerve injury. The life quality of the patients was evaluated by FACT/GOG-Ntx scale.,Results,2,During the study， 2 cases in the observation group and 5 cases in the control group were excluded， finally 67 cases in the observation group and 61 cases in the control group were included in the statistical analysis. ①After treatment， the symptom scores of hand and foot numbness， pain， fear of cold and fatigue in the observation group were significantly decreased compared with those before treatment （,P,<,0.05）， the symptom scores of hand and foot numbness and pain in the control group were also decreased compared with those before treatment （,P,<,0.05）， and the symptom scores of hand and foot numbness， pain， fear of cold and fatigue in the observation group were lower than those in the control group （,P,<,0.05）. ②After treatment， the total effective rate on Chinese medical syndrome was 46.27% in the observation group and 19.67% in the control group， and the effect of the observation group was better than that of the control group （,P,<,0.05）. ③After treatment， the total effective rate on the improvement of peripheral neuropathy classification was 85.07% in the observation group and 80.33% in the control group， and the curative effect of the observation group was better than that of the control group （,P,<,0.05）. ④After treatment， the SNCV and MNCV of median nerve and sural nerve in the two groups were significantly faster than those before treatment （,P,<,0.05）， and the SNCV and MNCV of median nerve and sural nerve in the observation group were also significantly faster than those in the control group （,P,<,0.05）. ⑤After treatment， the scores of TNS scale in the two groups were decreased compared with those before treatment （,P,<,0.05）， and the score of the observation group was lower than that of the control group （,P,<,0.05）. ⑥After treatment， the scores of FACT/GOG-Ntx scale in the two groups were decreased compared with those before treatment （,P,<,0.05）， and the score of the observation group was lower than that of the control group （,P,<,0.05）.,Conclusion,2,Compared with mecobalamin， Yiqi Wenyang Tongmai Formula can better improve the clinical symptoms and the peripheral neuropathy of the patients with CIPN， increase the peripheral nerve conduction velocity， thus improve the quality of life and enhance the confidence and compliance of the patients in the treatment of cancer.

关键词

化疗致周围神经病变益气温阳通脉方甲钴胺片临床研究

Keywords

chemotherapy induced peripheral neuropathyYiqi Wenyang Tongmai Formulamecobalamin tabletclinical study

references

LICHT T， KEILANI M， CRENENNA R. Chemotherapy-induced peripheral neuropathy （CIPN）［J］. Memo， 2021， 14（2）：34-38.

LU Y T， ZHANG P， ZHANG Q Y， et al. Duloxetine Attenuates Paclitaxel-Induced Peripheral Nerve Injury by Inhibiting p53-Related Pathways［J］. J Pharmacol Exp Ther， 2020， 373（3）：453-462.

YANG Y， HU L， WANG C Y， et al. p38/TF/HIF-α Signaling Pathway Participates in the Progression of CIPN in Mice［J］. Biomed Res Int， 2019（397）：1-11.

KAWASHIRI T， MINE K， KOBAYASHI D， et al. Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy； Experimental and Clinical Evidence［J］. Int J Mol Sci， 2021， 22（3）：1393-1417.

饶志璟，邓海滨，祝利民，等. 化疗药物所致周围神经毒性中西医研究进展［J］. 世界科学技术-中医药现代化， 2020， 22（4）： 1307-1314.

苏婉，徐振晔. 活血温阳通痹法治疗化疗致周围神经毒性临床观察［J］. 上海中医药大学学报， 2019， 33（4）： 39-42.

师悦. 通络蠲痹汤外洗防治化疗药物致周围神经毒性的临床研究［D］. 合肥：安徽中医药大学， 2017.

XIONG Z F， WANG T， GAN L， et al. Clinical efficacy of acupoint injection for chemotherapy-induced peripheral neuropathy of patients with breast cancer［J］. World J Acupunct Moxibustion， 2016， 26（2）： 20-24.

乔雪蕾. 当归四逆汤合身痛逐瘀汤联合中药外洗治疗化疗后周围神经病变临床研究［D］. 保定：河北大学，2019.

易嘉雯，林丽珠，董家辉. 外用和血通脉方治疗抗肿瘤化疗药所致周围神经毒性的临床疗效观察［J］. 中医临床研究， 2017， 9（3）： 49-51.

戴黎颖. 针灸治疗化疗所致周围神经病变临床研究的Meta分析［D］. 广州：广州中医药大学， 2019.

National Cancer Institute， National Institutes of Health， US Department of Health and Human Services. Common terminology criteria for adverse events v3.0 （CTCAE）［S/OL］. （2006-08-09）［2021-03-03］. http：//ctep.cancer.gov/protocol development/electronic applications/docs/ctcaev3.pdfhttp://ctep.cancer.gov/protocoldevelopment/electronicapplications/docs/ctcaev3.pdf.

王永炎，严世芸. 实用中医内科学［M］. 2版. 上海：上海科学技术出版社， 2009： 1926-1933.

郑筱萸. 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002： 81-85.

上海市卫生局. 上海市中医病证诊疗常规［M］. 2版. 上海：上海中医药大学出版社， 2003.

CAVALETTI G， FRIGENI B， LANZANI F， et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity： comparison with the National Cancer Institute-Common Toxicity Scale［J］. J Peripher Nerv Syst， 2007， 12（3）： 210-215.

CASTELINO S M， RODDAY A M， PEI Q， et al. Performance of FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy （CIPN） in pediatric Hodgkin lymphoma （HL） patients［J］. J Clin Oncol， 2019， 37（15suppl）： 10064.

HOU S， HUH B， KIM H K， et al. Treatment of Chemotherapy-Induced Peripheral Neuropathy： Systematic Review and Recommendations［J］. Pain Physician， 2018， 21（6）： 571-592.

GREENWALD M K， RUTERBUSCH J J， BEEBE-DIMMER J L， et al. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population［J］. Cancer， 2019， 125（2）： 269-277.

李世东，石建华，李学记. 甲钴胺联合谷胱甘肽防治消化系统肿瘤患者FOLFOX4方案化疗所致的神经毒性反应［J］. 中华肿瘤杂志， 2016， 38（8）： 632-635.

SMITH E M， PANG H， CIRRINCIONE C， et al. Effect of duloxetine on pain， function， and quality of life among patients with chemotherapy-induced painful peripheral neuropathy： a randomized clinical trial［J］. JAMA， 2013， 309（13）： 1359-1367.

魏晓晨，朱立勤，王春革，等. 维生素类药物预防化疗致周围神经毒性的疗效及安全性的Meta分析［J］. 中国现代应用药学， 2016， 33（4）： 476-484.

国家药典委员会. 中华人民共和国药典（2015年版）：一部［M］. 北京：中国医药科技出版社，2015：152-153， 302-303.

白海英，张凯雪，包芳，等. 黄芪和红芪对比研究进展［J］. 西北药学杂志， 2020， 35（3）： 460-466.

俞春林，杜正彩，郝二伟，等. 四类不同功效桂枝药对化学成分与药理作用的研究进展［J］. 中国实验方剂学杂志， 2020， 26（1）： 226-234.

杨志欣，汲丽丽，刘慧，等. 全蝎化学成分和药理作用的研究进展［J］. 中南药学， 2020， 18（9）： 1523-1529.

张晓娟，张燕丽，左冬冬. 川芎的化学成分和药理作用研究进展［J］. 中医药信息， 2020， 37（6）： 128-133.

赵孟煜. 自拟益气祛瘀通络方治疗奥沙利铂导致周围神经毒性（气虚血瘀型）的临床研究［D］. 福州：福建中医药大学， 2019.

王世昌，陈朝. 活血通痹方联合甲钴胺注射液治疗胃肠肿瘤化疗致周围神经病变的疗效观察［J］. 中国实用神经疾病杂志， 2014， 17（7）： 96-97.

李海金，陈亚男，董良，等. 中药熏洗联合甲钴胺治疗化疗致周围神经病变临床观察［J］. 浙江中西医结合杂志， 2019， 29（4）： 298-301.

浏览量

449

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

大黄附子汤治疗脓毒症致急性胃肠损伤的临床研究

大承气汤联合西医常规治疗干预脓毒症伴急性胃肠损伤的临床研究

中药外用治疗难愈性创面的临床研究进展

加味下瘀血颗粒联合醋酸泼尼松片治疗特发性肺间质纤维化气阴两虚、肺络痹阻证的临床研究